Chemours Q2 2022 Earnings Report
Key Takeaways
Chemours reported record net sales of $1.9 billion, up 16% year-over-year, driven by strong demand across all segments. Record Adjusted EBITDA for both TSS and APM. The company is now targeting the high end of Adjusted EBITDA guidance and increasing Free Cash Flow outlook.
Record Net Sales of $1.9 billion, up 16% year-over-year, including record Net Sales in all three segments
Net Income of $201 million with EPS of $1.26, up $0.87 year-over-year
Adjusted Net Income of $302 million with Adjusted EPS of $1.89, up $0.69 year-over-year
Adjusted EBITDA of $475 million, up 30% year-over-year
Chemours
Chemours
Chemours Revenue by Segment
Forward Guidance
Chemours anticipates achieving the high end of its full year Adjusted EBITDA range and are raising its cash flow outlook to greater than $600 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income